Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-104

64 evidence topics · 6 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“N/A”
Interventional model“Single Group Assignment”
Model description“open-label, follow-up study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (actual)“217”
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
MeasureQuoted record
Enrollment (actual)“217”
Overall number of baseline participants“217”
Overall number of participants analyzed, clinical remission at week 48“217”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MeasureParticipants
Started“217”
Completed“164”
Not completed“53”
Adverse event“16”
Death“1”
Lack of efficacy“3”
Lost to follow-up“1”
Other reason (e.g., Ukraine Crisis)“10”
Physician decision“4”
Pregnancy“4”
Withdrawal by subject“14”
Baseline characteristics
Demographic and baseline characteristics in the published report
CharacteristicTotal (N = 217)
Age, years, mean (SD)“42.1 (13.8)”View highlighted excerpt for this quote
Male, n (%)“133 (61.3)”View highlighted excerpt for this quote
Female, n (%)“84 (38.7)”View highlighted excerpt for this quote
Obefazimod 25 mg during induction, n (%)“58 (26.7)”View highlighted excerpt for this quote
Obefazimod 50 mg during induction, n (%)“51 (23.5)”View highlighted excerpt for this quote
Obefazimod 100 mg during induction, n (%)“53 (24.4)”View highlighted excerpt for this quote
Placebo during induction, n (%)“55 (25.3)”View highlighted excerpt for this quote
Naïve to biologics or JAK inhibitors, n (%)“119 (54.8)”View highlighted excerpt for this quote
Inadequate response to biologics or JAK inhibitors, n (%)“98 (45.2)”View highlighted excerpt for this quote
Inadequate response to 2 or more biologics or JAK inhibitors, n (%)“70 (71.4)”View highlighted excerpt for this quote
Concomitant corticosteroids, n (%)“120 (55.3)”View highlighted excerpt for this quote
Concomitant 5-ASA, n (%)“159 (73.3)”View highlighted excerpt for this quote
Fecal calprotectin, µg/g, mean (SD)“900.1 (1574.5)”View highlighted excerpt for this quote
Efficacy results
Primary outcome in the posted results: clinical remission at week 48 (of 217)
OutcomeParticipants
Clinical remission at week 48“119”
Secondary outcomes in the posted results: number of participants (of 217)
OutcomeWeek 48Week 96
Clinical response“177”“158”
Endoscopic improvement“133”“128”
Endoscopic remission“72”“78”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events over 96 weeks
Adverse events in the posted results: participants affected / at risk (%)
EventABX464 50 mg
All-cause mortality“1/217 (0.46%)”
Serious adverse events, total“18/217 (8.29%)”
Other adverse events, total“148/217 (68.20%)”
COVID-19“31/217 (14.29%)”
Headache“25/217 (11.52%)”
Colitis ulcerative“17/217 (7.83%)”
Nasopharyngitis“15/217 (6.91%)”
Study limitations
Summary

ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.